Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations.
Engaged in the discovery, development, and commercialization of innovative pharmaceuticals for the treatment of many diseases, either directly or indirectly. Directly treating a disease would involve some sort of drug that could attack the infection itself. An indirect treatment may involve a drug that's used to enhance the body's own antibody production so those antibodies can attack the infection themselves. Not only do some of these companies develop drugs for human use, a good number of them also work on animal or plant diseases as well.
|
| Totals |
Company |
Industry |
| Sales: |
$49.2 Mil |
$103,380.7 Mil |
| Market Cap: |
$211.7 Mil |
$388,289.7 Mil |
| Analysts Recommendation: |
Buy |
Buy |
|
|
| Averages |
Company |
Industry |
 |
| Growth |
| Historic Revenue: |
250.5% |
46.3% |
| Estimated Revenue: |
N/A |
(7.3%) |
| Historic Earnings: |
N/A |
(63.9%) |
| Estimated Earnings: |
N/A |
30.0% |
| Stock Price (1 Year): |
(22.0%) |
33.8% |
| Cash per Share: |
407.6% |
25.7% |
| Dividend: |
N/A |
N/A |
| Price |
| Trailing PE: |
N/A |
N/A |
| Forward PE: |
N/A |
38.1 |
| Price-to-Sales: |
4.5 |
N/A |
| Price-to-Book: |
9.1 |
7.9 |
| Dividend Yield: |
N/A |
N/A |
| Market Cap: |
$211.7 Mil |
$12,943.0 Mil |
| Operations |
| Net Margin: |
(2.0%) |
(219.8%) |
| Gross Margin: |
86.5% |
83.3% |
| Return on Equity: |
(.2) |
(1.5) |
| Return on Assets: |
(.1) |
(.2) |
| Balance Sheet |
| Current Ratio: |
2.9 |
5.5 |
| Quick Ratio: |
2.7 |
5.3 |
| Cash Ratio: |
2.3 |
4.7 |
| Debt-to-Equity: |
1.5 |
2.8 |
| Interest Coverage: |
.4 |
.7 |
| Technicals |
| Relative-Strength Index: |
37.0 |
N/A |
|
|
|
